Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review. by Patel, R et al.
  1Patel R, et al. BMJ Open Resp Res 2020;7:e000756. doi:10.1136/bmjresp-2020-000756
To cite: Patel R, Naqvi SA, 
Griffiths C, et al. Systemic 
adverse effects from 
inhaled corticosteroid use 
in asthma: a systematic 
review. BMJ Open Resp Res 
2020;7:e000756. doi:10.1136/
bmjresp-2020-000756
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjres- 2017- 000756).
RP and SAN are joint first 
authors.
Received 27 August 2020
Revised 8 October 2020
Accepted 19 October 2020
1Faculty of Medicine, Imperial 
College London, London, UK
2Centre for Primary Care and 
Public Health, Queen Mary 
University of London, London, 
UK
3National Heart and Lung 
Institute, Imperial College 
London, London, UK
Correspondence to
Dr Chloe I Bloom;  
 chloe. bloom06@ imperial. 
ac. uk
Systemic adverse effects from inhaled 
corticosteroid use in asthma: a 
systematic review
Roshni Patel,1 Sumrah A Naqvi,1 Chris Griffiths,2 Chloe I Bloom3
Asthma
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background Oral corticosteroid use increases the risk 
of systemic adverse effects including osteoporosis, bone 
fractures, diabetes, ocular disorders and respiratory 
infections. We sought to understand if inhaled 
corticosteroid (ICS) use in asthma is also associated with 
increased risk of systemic effects.
Methods MEDLINE and Embase databases were searched 
to identify studies that were designed to investigate ICS- 
related systemic adverse effects in people with asthma. 
Studies were grouped by outcome: bone mineral density 
(BMD), respiratory infection (pneumonia or mycobacterial 
infection), diabetes and ocular disorder (glaucoma or 
cataracts). Study information was extracted using the PICO 
checklist. Risk of bias was assessed using the Cochrane 
Risk of Bias tool (randomised controlled trials) and Risk 
of Bias In Non- randomised Studies of Interventions- I tool 
(observational studies). A narrative synthesis was carried 
out due to the low number of studies reporting each 
outcome.
Results Thirteen studies met the inclusion criteria, 2 trials 
and 11 observational studies. Study numbers by outcome 
were: six BMD, six respiratory infections (four pneumonia, 
one tuberculosis (TB), one non- TB mycobacteria), one 
ocular disorder (cataracts) and no diabetes. BMD studies 
found conflicting results (three found loss of BMD and 
three found no loss), but were limited by study size, short 
follow- up and lack of generalisability. Studies addressing 
infection risk generally found positive associations 
but suffered from a lack of power, misclassification 
and selection bias. The one study which assessed 
ocular disorders found an increased risk of cataracts. 
Most studies were not able to fully adjust for known 
confounders, including oral corticosteroids.
Conclusion There is a paucity of studies assessing 
systemic adverse effects associated with ICS use in 
asthma. Those studies that have been carried out present 
conflicting findings and are limited by multiple biases 
and residual confounding. Further appropriately designed 
studies are needed to quantify the magnitude of the risk 
for ICS- related systemic effects in people with asthma.
INTRODUCTION
Asthma is a highly prevalent global disease; 
for example, around 8% of adults in the UK 
and the USA have active asthma.1 2 Since the 
1970s, inhaled corticosteroids (ICS) have 
been the mainstay of treatment—significantly 
reducing morbidity and mortality, thus they 
are recommended as first- line preventer 
treatment in national and international 
guidelines.3–5 For most people, maximal clin-
ical benefit can be achieved with low- dose 
ICS.6–8 Yet in the UK, the number of adults 
with asthma that are prescribed medium- 
dose or high- dose ICS has increased consid-
erably over the past decade (to around 70% 
in 2017).9 Oral corticosteroid use in people 
with asthma has been found to increase 
the risk of conditions including osteopo-
rosis, bone fractures, cataracts, pneumonia, 
opportunistic lung infections, diabetes and 
obesity.10 Studies evaluating the dose equiva-
lence of oral corticosteroids to ICS, in terms 
of systemic effects, found most of the oral 
corticosteroid- sparing effect that occurs with 
high- dose ICS is ascribed to their systemic 
absorption; suggesting high- dose ICS requires 
similar consideration as starting maintenance 
low- dose oral corticosteroids.11 But patients at 
higher risk of systemic side effects (those that 
are already diagnosed with osteopenia, osteo-
porosis, diabetes and cataracts) are not pref-
erentially started on low- dose ICS or stepped 
down from higher ICS doses,9 even though 
Key messages
What is the key question?
 ► Do inhaled corticosteroids in people with asthma in-
crease the risk of systemic adverse effects that are 
known to occur with oral corticosteroid use?
What is the bottom line?
 ► There are few studies addressing this question, and 
those studies are limited by multiple biases, but they 
suggest an increased risk of bone mineral density 
loss, respiratory infections and cataracts.
Why read on?
 ► This review reports on the few studies that have 
been carried out on this topic, and highlights current 
evidence gaps.
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people with asthma do consider potential side effects a 
priority when choosing treatment.12
The benefits of an ICS undoubtedly outweigh the risks 
when used in clinically effective doses, however, long- 
term ICS use may cause systemic side effects.13 There has 
only been one previous systematic review (published in 
1999) of all major potential adverse systemic effects asso-
ciated with ICS, including people with asthma. Due to 
a dearth of studies the author was unable to perform a 
meta- analysis, except for the numerous studies evaluating 
adrenal insufficiency.14 The aim of this present system-
atic review was to review the latest scientific evidence of 
adverse systemic effects associated with ICS use in asthma 
(excluding adrenal insufficiency which was recently 
reviewed elsewhere).15
METHODS
The systematic review protocol was registered with the 
International Prospective Register of Systematic Reviews, 
registration number: CRD42020187770 and we followed 
the guidelines published by the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses Consor-
tium (PRISMA).16
Study objectives
Our objective was to quantify, in adults with asthma, any 
association between adverse systematic effects (known to 
occur with oral corticosteroids) and ICS use. We sought 
to assess the following effects: bone mineral loss (bone 
density or fractures), respiratory infections (pneumonia, 
tuberculosis (TB), or non- TB mycobacteria), ophthalmic 
effects (cataracts/glaucoma) and diabetes.
Literature search
We systematically searched MEDLINE and Embase (from 
10 June 1999 through 10 June 2020) using both Medical 
Subject Headings terms and free- text searching to iden-
tify literature related to asthma, ICS- containing medica-
tion and the systemic adverse effects listed in the objec-
tives (online supplemental table 1). These three concepts 
were combined using the Boolean operator ‘AND’. The 
database search was supplemented by a manual scan of 
the reference lists of included studies.
Selection of studies
We selected randomised controlled trials (RCTs) and 
observational studies that included adults with asthma 
(≥18 years), or that included at most 20% of the study 
population aged 12–18 years. We considered obser-
vational studies where at least one of our outcomes of 
interest was measured as the primary outcome, and 
primary or secondary analyses of RCTs. The exposure 
considered for this review were ICS- containing inhalers 
(single component or dual component with a long- acting 
β agonist); those not exposed were using a placebo or 
non- ICS- containing medication. For observational 
studies only, we included studies where the control group 
could contain people without asthma. We only included 
studies that were designed to evaluate at least one of our 
outcomes of interest: bone density loss (measure by ultra-
sound or X- ray absorptiometry), pneumonia, TB, non- TB 
mycobacteria, cataracts, glaucoma and diabetes (new 
diagnosis or hyperglycaemia). Articles were excluded 
if they contained <100 patients that met the inclusion 
criteria, mixed- study population encompassing more 
than 10% of people with COPD (chronic obstructive 
pulmonary disease) or were a study of pregnant women. 
Abstracts, case histories, reviews/pooled analysis, guide-
lines, commentaries, animal/in vitro studies and articles 
not written in English language were also excluded.
Data extraction, quality assessment and data synthesis
Data were extracted following predetermined criteria 
based on the PICO (Patient Information Comparison 
Outcome) checklist (online supplemental table 2). Study 
details included: study name; patient number; length of 
follow- up; study inclusion and exclusion criteria; popu-
lation characteristics including how asthma was defined, 
gender and age range; primary and secondary outcomes; 
non- ICS comparison; ICS type where reported; 
confounding factors; crude and adjusted effect esti-
mates; statistical analysis; and any additional notes. Two 
reviewers extracted relevant data, which were compared, 
and inconsistencies discussed.
Quality of RCTs were assessed using the Cochrane 
Risk of Bias tool. Quality of studies was reported as 
high, moderate, low bias or unclear. Quality of obser-
vational studies was assessed using Risk of Bias In Non- 
randomised Studies of Interventions. Quality of studies 
was reported as critical, serious, moderate or low bias. 
Studies were grouped according to study design (RCT 
or observational), outcome (including by measurement 
tool, for example, bone density was measured using 
ultrasound, single or dual energy X- ray absorptiometry) 
and effect estimate (HR or OR). There were no more 
than two studies in each group, therefore it was deemed 
inappropriate to calculate pooled effect estimates, and a 
narrative synthesis was conducted.
Patient and public involvement statement
Six patients, from a community asthma clinic and a large 
UK asthma charity, were consulted in a focus group as to 
their perceived need of this review and the study design, 
specifically regarding the inclusion and exclusion criteria 
to be used. Two patients subsequently critically reviewed 
the manuscript.
RESULTS
Study selection and characteristics
Following our database searches, we identified a total of 
5102 studies. After screening for criteria outlined in the 
methods and illustrated in the PRISMA flow chart, 5089 
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papers were excluded, leaving a total of 13 articles to be 
included in this systematic review (online supplemental 
figure 1 and tables 1–3).
Inclusion and exclusion criteria within papers
A common inclusion criterion was for patients to have a 
minimum number of months (for example, some studies 
had a minum of 6 months) since their asthma was first 
diagnosed, although many papers failed to provide a defi-
nition for the diagnosis of asthma (online supplemental 
table 3a- d). Two studies specified that patients should 
have mild asthma (according to forcedexpiratory volume 
in 1 s or peak flow readings prebronchodilator) but no 
study specified moderate or severe asthma. Common 
exclusion criteria that many, but not all, studies included: 
COPD diagnosis/hospital admission for COPD exacerba-
tions, use of oral/parenteral steroids in a specified time 
prestudy commencement and medical conditions known 
to affect the outcomes being measured.
Bone density studies
Six studies specified the measurement of bone mineral 
density (BMD) as the primary outcome17–22 (table 1). 
The studies (four observational, two RCT) each included 
under 250 participants, except one observational study 
which included 8624 participants.21 BMD was measured 
using ultrasound or X- ray absorptiometry (single or 
dual), or a combination of both, and in different bones 
(wrist, femur, hip and spine); therefore, findings could 
not be directly compared between more than two trials. 
Three of the studies found a decrease in BMD,18 19 21 
while three found no change in BMD;17 20 22 one found 
an increased risk of fractures but no loss of BMD. Study 
follow- up varied between 6 months to several years and 
the total time of ICS exposure was not reported. In addi-
tion, previous OCS (oral corticosteroids) use was not 
accounted for in two of the four observational studies.20 22
Respiratory infection studies: pneumonia
Four observational studies identified pneumonia, diag-
nosed by a general practitioner, hospital admission or 
insurance codes, as a primary outcome (table 2). All 
four studies found an increased risk of pneumonia,23–26 
although one study found the risk was only increased 
with fluticasone, not budesonide;25 however, it was likely 
the subanalysis was underpowered due to the low event 
rates. Another study due to its cross- sectional design had 
a high risk of reverse causality,26 one study had a high 
risk of misclassification as it did not include hospitalised 
pneumonia,23 and the fourth study only included people 
aged 12–35 years old.24
Respiratory infection studies: mycobacterial infection
Two case- control studies measured the odds of mycobac-
terial infection in patients with asthma on ICS to people 
without asthma and not on ICS (table 2). One study used 
a South Korean database (n=2779 patients aged over 20 
years) to measure the odds of TB,27 the other study used 
a Canadian administrative database (n=1091 patients 
aged over 66 years) to measure the risk of TB and non- 
tuberculous mycobacterial pulmonary disease (NTM- 
PD);28 both studies found approximately 50% increase in 
the odds of TB, although this was not statistically signif-
icant in the study by Brode et al. However, there was a 
statistically significant increase in the odds of NTM- PD 
associated with fluticasone, but not budesonide.
Ocular disorder studies
One case- control study analysed the impact of ICS on the 
development of cataracts in a primary care population 
of over 30 000 patients aged above 40 years (table 3). 
Controls had no previous use of ICS and findings were 
adjusted for OCS use.29 Exposed patients had to have at 
least one ICS prescription in a 180- day period, but accu-
mulative ICS use was not accounted for. Adjusted results 
found a 5% significant increase in the odds of developing 
cataract in patients using an ICS.
Risk of bias
With regards to the RCTs, both successfully demonstrated 
low levels of selection bias,17 19 but one showed a poten-
tially high risk of performance bias by keeping the study 
‘open’ and unblinded to participants and personnel19 
(table 4). We found varying levels of bias in terms of obser-
vational studies (table 5). Six of the 11 studies had at least 
a moderate risk of bias due to confounding, including 
not accounting for any confounders,22 or only one to 
three confounders,20 25 29 or not including oral corti-
costeroids—potentially the largest confounder.20 22 24–26 
Seven studies had at least a moderate risk of selection 
bias,18 20–25 for example, by only selecting a limited young 
age range at lower risk of BMD loss.17–19 Seven studies 
showed at least moderate bias in intervention classifica-
tion;18 22–24 26 27 29 many did not take any account of how 
long participants were on ICS for.18 21–23 25 26 28 29 Only 
three studies had low bias of missing data,19 24 29 most did 
not report on missing data20–22 25–28 and one had serious 
bias risk.23 Three studies had at least moderate risk of bias 
in measurement of outcomes20 23 26 and three studies did 
not report if the investigators were aware of the inter-
vention status.21 22 28 All studies had low risk of bias in 
reporting results.17–29
DISCUSSION
This systematic review investigated the potential risk of 
adverse systemic effects, known to occur with OCS, in 
people with asthma using ICS. We found 2 RCTs and 
11 observational studies meeting the inclusion criteria. 
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The most common reason for excluding articles was that 
people with asthma were not identified, either because 
the reason for ICS use was not reported or because the 
effects on people with asthma were not reported sepa-
rately from the effects on people with COPD.
The main outcomes of studies eligible to be included 
were loss of BMD and risk of a respiratory infection. 
However, due to small sample size, insufficiently recorded 
ICS and/or OCS exposure, and studies using alternative 
ways of measuring BMD, there is currently a deficiency 
of evidence to determine if ICS reduces BMD in people 
with asthma. Furthermore, only one study specifically 
addressed the risk of bone fractures. The four studies 
addressing risk of pneumonia were much larger and 
mostly found an increased risk, but the studies had signif-
icant bias—including misclassification, due to the lack of 
hospital diagnosed pneumonia—and lack of generalis-
ability, including a study population of only young adults. 
Two studies assessed pulmonary mycobacterial infection 
risk, and both reported an elevated risk with ICS, but the 
studies’ low outcome prevalence is likely to have caused 
a lack of statistical power to make firm conclusions. 
Only one study that measured an ocular disorder as the 
outcome was eligible to be included. The study, which 
had moderate bias in the confounding and intervention 
classification categories, found an increased risk associ-
ated with ICS use.
Although most of the studies in this systematic review 
had biases and limitations in generalisability, there 
is a suggestion that ICS use in people with asthma 
can lead to systemic adverse effects. This is perhaps 
not surprising as all ICS have been found to exhibit 
dose- related systemic adverse effects when measuring 
adrenal suppression,14 and high dose ICS has been 
shown to have an equivalent systemic absorption as 
low dose OCS.11 In addition, several adverse systemic 
effects have been found to be associated with ICS use 
in people with COPD, although caution should be used 
in extrapolating findings in people with COPD to those 
with asthma. First, people with COPD tend to be older, 
have more comorbidities, have higher exposure to ciga-
rette smoke and have differing underlying pulmonary 
immunopathology and systemic inflammation, which 
may affect the risk of developing adverse effects. For 
example, osteoporosis has been found to be increased 
in people with COPD, even without ICS use.30 Second, 
many people with asthma use much higher doses of 
ICS and have used ICS for much of their lifetime—
unlike COPD, where lower doses of ICS are licensed as 
treatment and patients typically start ICS treatment at 
Table 3 Description of observational studies with an ocular disorder as an outcome
Primary author Smeeth29
Year 2003
Study design Case- control study
Length of study/follow- up At least 180 days
Population UK primary care electronic medical records (Clinical Practice Research Datalink)
Sample size 15 479 people with cataract and 15 479 controls
Age range 40 years +
Asthma diagnosis definition N/A
ICS type (drug/name) Beclomethasone, budesonide, fluticasone
Control/comparison General population matched controls with no ICS ever
Primary outcome Cataracts
Secondary outcomes of study N/A
Statistical analysis Conditional logistic regression
Adjusted covariates Only OCS and consultation rate for the asthma effect estimate
Crude results 1.52 (95% CI 1.41 to 1.65)
Adjusted results 1.05 (95% CI 0.95 to 1.16)
ICS, inhaled corticosteroid; OCS, oral corticosteroids.
Table 4 Risk of bias assessment of trials
Study Outcome
Random 
sequence
Allocation 
concealment
Reporting 
bias
Other 
bias
Performance 
bias
Detection 
bias
Attrition 
bias
Tattersfield et 
al19
Bone 
density
Low Unclear Low Unclear High Low Unclear
Kemp et al17 Bone 
density
Low Low Low Unclear Low Low Low
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between 60 years and 70 years of age.31 There is little 
debate that ICS use in people with COPD is associated 
with elevated risk of pneumonia.32 Studies of patients 
with COPD have also found an increased risk of TB in 
at- risk populations,33 a modest but statistically signifi-
cant augmented risk of fractures34 and in studies not 
distinguishing between patients with asthma and COPD, 
the risk of cataracts is around 25% for each 1000 mcg 
per day (beclometasone equivalent).35 Very few studies 
have assessed the risk of new- onset diabetes or wors-
ening glycaemia, allied to ICS use, in any population.36
Limitations
The main limitation of this review is the small number 
of studies eligible to be included, which precludes the 
calculation of an overall effect estimate for any of the 
outcomes. Furthermore, in the BMD articles, different 
studies used different density measurement tools, 
in different bones. The lack of adequate control for 
confounding from OCS exposure represents another 
inherent limitation. It was not possible to draw conclu-
sions on the association between systemic adverse 
effects and the dose, duration or type of ICS from 
the included studies. In studies with a short follow- up 
it was not possible to consider longer- term adverse 
effects that may occur, such as bone mineral loss. In 
this systematic review we have chosen not to include all 
trials reporting adverse effects as these rely on sponta-
neous adverse event reports in short- term clinical trials, 
with no formal measurement of the outcome; further-
more, there is always a high risk of selection bias as 
only around 10% of people with asthma are eligible to 
participate in clinical trials.
CONCLUSIONS
Asthma is a highly prevalent disorder that in many 
people requires regular ICS to ensure symptom 
control and prevent asthma attacks, most of whom are 
prescribed medium dose or high dose ICS.2 Yet, we 
found in this review that surprisingly few studies have 
assessed the potential risk, in an asthma population, 
of the known adverse systemic effects that accompany 
OCS use. While these limited studies do suggest ICS 
use increases the risk of respiratory infections, cata-
racts and loss of BMD in people with asthma, there 
were several biases and limitations associated with the 
studies. A key message from this review is the urgent 
need for further well- controlled and detailed longitu-
dinal cohort studies to quantify the nature and magni-
tude of the risk of systemic adverse effects. These 
studies should try to establish which ICS drugs, which 
patients and what doses are associated with the highest 
risk for each outcome. This information is crucial 
for making informed, shared decisions with patients 
about how to manage their asthma. Although the risk 
of side effects is often not considered by primary care T
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physicians, it is considered by patients to be a priority in 
treatment choices;12 37 bridging this evidence gap will 
help improve joint management decisions.
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